EssilorLuxottica Joins Global Collaborative Community to Advance Ophthalmic Innovation

EssilorLuxottica has officially joined the Collaborative Community of Ophthalmic Innovation (CCOI), a global, multi-stakeholder initiative focused on transforming breakthrough science into impactful, real-world eye care solutions. The CCOI unites patients, clinicians, researchers, regulators, and industry leaders with the shared goal of accelerating innovation across the ophthalmic landscape and strengthening the eye's role within the broader healthcare ecosystem.

Through this membership, EssilorLuxottica will integrate its strengths in optical engineering and digital health with the CCOI’s collaborative and consensus-driven framework, aiming to translate emerging science into measurable outcomes for patients worldwide.

Supporting Collaborative Research and Innovation in Eye Health

“Joining the Community at the highest level of industry participation reflects our dedication to advancing ophthalmic science through industry collaboration,” said Dr. Norbert Gorny, Chief Scientific Officer at EssilorLuxottica.
“By integrating our capabilities with the Community’s collective knowledge, we aim to accelerate translational research and clinical breakthroughs that will redefine how eye diseases are detected, managed, and ultimately prevented. We are also proud to bring capabilities from across our Group, including Heidelberg Engineering, whose decades of leadership in imaging and data science will help drive the next generation of evidence-based ophthalmic innovation.”

EssilorLuxottica joins CCOI as a Vision Architect, the highest tier of industry participation, placing the company at the forefront of key collaborative initiatives.

“We are honored to welcome EssilorLuxottica as a Vision Architect of the Collaborative Community on Ophthalmic Innovation,” said Malvina Eydelman, MD, Chief Executive Officer of CCOI.
“Through this leadership role, EssilorLuxottica will help shape global standards and scientific frameworks by driving CCOI’s Endpoints Consensus Workshops and international standards initiatives—advancing a unified, patient-centered foundation for ophthalmic innovation worldwide.”

Strategic Focus Areas: Myopia, AI, AMD, and More

As an active member of the CCOI, EssilorLuxottica will contribute to several critical scientific workstreams, including:

       • Myopia management

       • Oculomics

       • Artificial intelligence

       • Age-related macular degeneration (AMD)

       • Glaucoma

The company plans to leverage its global scale and technology platforms to accelerate progress in these areas and support the development of next-generation tools and diagnostics that advance eye care delivery and outcomes globally.